BACKGROUND: The rate of progression to cirrhosis varies among individuals chronically infected with the hepatitis C virus (HCV). Coagulation pathway activation in models of hepatic fibrosis suggests variation in coagulation pathway components may influence the rate of fibrosis. We hypothesised that polymorphisms of the coagulation factors II and V affect the rate of progression to cirrhosis in HCV infected subjects. METHODS: We studied the relationship between rate of fibrosis (calculated by dividing the fibrosis stage by duration of infection) and genotypes of specific coagulation pathway genes in 352 White European patients infected with HCV. Genotyping was performed using reverse line blot hybridisation. RESULTS: The rate of fibrosis was significantly higher in patients with the factor V Leiden genotype (Arg560Gln) (ANOVA, p=0.004). In disease association studies, a significant association was seen (Fisher's exact test, p=0.029; odds ratio 3.28 for fast progression to cirrhosis (expected to reach cirrhosis in less than 30 years) if heterozygous for factor V Leiden). No associations were seen between factor II genotype and fibrosis rate. CONCLUSIONS: Possession of the factor V Leiden polymorphism significantly increases the risk of rapid disease progression in HCV, suggesting a role for the coagulation system in the pathogenesis of fibrotic liver disease.
BACKGROUND: The rate of progression to cirrhosis varies among individuals chronically infected with the hepatitis C virus (HCV). Coagulation pathway activation in models of hepatic fibrosis suggests variation in coagulation pathway components may influence the rate of fibrosis. We hypothesised that polymorphisms of the coagulation factors II and V affect the rate of progression to cirrhosis in HCV infected subjects. METHODS: We studied the relationship between rate of fibrosis (calculated by dividing the fibrosis stage by duration of infection) and genotypes of specific coagulation pathway genes in 352 White European patients infected with HCV. Genotyping was performed using reverse line blot hybridisation. RESULTS: The rate of fibrosis was significantly higher in patients with the factor V Leiden genotype (Arg560Gln) (ANOVA, p=0.004). In disease association studies, a significant association was seen (Fisher's exact test, p=0.029; odds ratio 3.28 for fast progression to cirrhosis (expected to reach cirrhosis in less than 30 years) if heterozygous for factor V Leiden). No associations were seen between factor II genotype and fibrosis rate. CONCLUSIONS: Possession of the factor V Leiden polymorphism significantly increases the risk of rapid disease progression in HCV, suggesting a role for the coagulation system in the pathogenesis of fibrotic liver disease.
Authors: S Cheng; M A Grow; C Pallaud; W Klitz; H A Erlich; S Visvikis; J J Chen; C R Pullinger; M J Malloy; G Siest; J P Kane Journal: Genome Res Date: 1999-10 Impact factor: 9.043
Authors: D Thorburn; G Curry; R Spooner; E Spence; K Oien; D Halls; R Fox; E A B McCruden; R N M MacSween; P R Mills Journal: Gut Date: 2002-02 Impact factor: 23.059
Authors: J Cui; D T Eitzman; R J Westrick; P D Christie; Z J Xu; A Y Yang; A A Purkayastha; T L Yang; A L Metz; K P Gallagher; J A Tyson; R D Rosenberg; D Ginsburg Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma Journal: Nature Date: 1994-05-05 Impact factor: 49.962
Authors: K S Brown; M J Keogh; N Tagiuri; M J Grainge; J S Presanis; S D Ryder; W L Irving; J K Ball; R B Sim; T P Hickling Journal: Clin Exp Immunol Date: 2007-01 Impact factor: 4.330
Authors: Douglas A Simonetto; Hui-yin Yang; Meng Yin; Thiago M de Assuncao; Jung Hee Kwon; Moira Hilscher; Shuchong Pan; Liu Yang; Yan Bi; Arthur Beyder; Sheng Cao; Robert D Simari; Richard Ehman; Patrick S Kamath; Vijay H Shah Journal: Hepatology Date: 2015-01-05 Impact factor: 17.425
Authors: L G Poole; A Pant; K S Baker; A K Kopec; H M Cline-Fedewa; S E Iismaa; M J Flick; J P Luyendyk Journal: J Thromb Haemost Date: 2018-12-10 Impact factor: 5.824
Authors: J Gillibert Duplantier; L Dubuisson; N Senant; G Freyburger; I Laurendeau; J-M Herbert; A Desmoulière; J Rosenbaum Journal: Gut Date: 2004-11 Impact factor: 23.059